Harrow Launches Vigamox in the United States

Harrow announced the completion of the transfer of the new drug application (NDA) for Vigamox (moxifloxacin hydrochloride ophthalmic solution) 0.5% to the company. Vigamox, which is a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms, is now available in the United States under the Harrow name.

The company advised that Vigamox can be ordered directly through Harrow’s dedicated customer service ordering partner, Cardinal’s Cordlogistics, which includes a wholesaler distribution system encompassing McKesson and AmerisourceBergen.

In January 2023, the company announced the acquisition of the United States commercial rights to Vigamox along with four other FDA-approved ophthalmic products from Novartis.

Vigamox is the fourth product from the acquisition that has completed the NDA transfer process and become commercially available under the Harrow name. The company previously announced the completion of the NDA transfer process for Ilevro (nepafenac ophthalmic suspension) 0.3%, Nevanec (nepafenac ophthalmic suspension) 0.1%, and Maxidex (dexamethasone ophthalmic suspension) 0.1%.